2434. Review of Linezolid (LZD) Use and Onset of Toxicity in 4 Belgian Hospital Centers: A Retrospective Study

BACKGROUND: LZD is approved (FDA label and Belgian Summary of Product Characteristics [SmPC]) for the treatment of SSSTI and pneumonia caused by Gram-positive organisms (mainly MRSA and VRE) only. Yet IDSA recommendations for MRSA infections also position LZD for osteomyelitis and as an alternative...

Descripción completa

Detalles Bibliográficos
Autores principales: Thirot, Helene, Briquet, Caroline, Frippiat, Frédéric, Jacobs, Frederique, Holemans, Xavier, Tulkens, Paul, Spinewine, Anne, Bambeke, Francoise Van
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254233/
http://dx.doi.org/10.1093/ofid/ofy210.2087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254233/
http://dx.doi.org/10.1093/ofid/ofy210.2087

Ejemplares similares